Services
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Antibody (BsAb/ADC) & Biologic Efficacy Study Service
Are you currently facing challenges with long drug development cycles, difficulty in predicting clinical outcomes, or the complexity of managing novel modalities like bispecifics and ADCs? Our NHP Antibody & Biologic Efficacy services help you accelerate your program and gain critical translational insights through our advanced NHP models and expertise in assessing the efficacy and safety of next-generation biologics. We provide a robust platform to bridge the gap between preclinical data and clinical success.
Introduction of NHP Cell Therapy Models
What Our Service Is
Our NHP Antibody & Biologic Efficacy services provide a comprehensive preclinical platform for the in vivo evaluation of therapeutic antibodies, bispecifics, and ADCs. NHPs are the most physiologically relevant model for human studies, offering a unique opportunity to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of novel biologics before they enter the clinic. This is due to the high degree of genetic, anatomical, and immunological similarity between NHPs and humans, which allows for a more accurate prediction of clinical response and potential toxicities. We offer these services for a wide range of applications:
- Translational Efficacy Studies: Evaluating the therapeutic effect of bispecific antibodies and ADCs in disease models that closely mimic human conditions.
- PK/PD Profiling: Understanding how a drug behaves in the body and its biological effect over time, which is crucial for determining optimal dosing strategies and mitigating safety concerns, particularly for complex modalities like ADCs where drug-payload ratios and linker stability are critical.
- Off-Target Toxicity and Safety Assessment: Identifying and characterizing potential off-target toxicities and adverse events to ensure the safety of your biologic, which is particularly important for ADCs with highly potent payloads. For instance, some ADC payloads can cause hematological toxicities like neutropenia, which can be evaluated effectively in NHP models.
Why Choose Us?
At Creative Biolabs, we understand the challenges of modern drug development. The complexity of new biologic modalities, from bispecific antibodies designed to engage two different targets to ADCs that require precise delivery of a cytotoxic payload, demands a more sophisticated preclinical approach. The pain point of unpredictable preclinical results and subsequent clinical failures can be mitigated by leveraging our NHP expertise. We create value for our customers by:
- Bridging the Translational Gap: Our NHP models offer a crucial link between in vitro data and human clinical trials, providing data that is highly predictive of clinical outcomes.
- Accelerating Timelines: Our optimized workflows and experienced team ensure that your preclinical studies are executed efficiently, saving valuable time and resources.
- Enhancing Data Quality: We provide high-quality, in-depth data and analysis, helping you make informed decisions about your drug candidate.
Fig.1 Anti-drug antibodies assay configurations employed in cynomolgus monkeys.1
Key Benefits of Our Service
The Creative Biolabs advantage is built on a foundation of scientific rigor, a robust infrastructure, and a client-centric approach. We offer a platform designed to provide accurate and actionable data for your bispecific and ADC programs.
- Rapid Response and Study Initiation: Our streamlined protocol design and study-ready NHP resources enable us to initiate projects with unmatched speed, getting you the data you need faster.
- Extensive NHP Resources: We maintain a large, healthy colony of NHPs (Cynomolgus and rhesus macaques), ensuring a consistent supply of high-quality animals for your studies. This provides flexibility and scalability for programs of all sizes.
- Full Customization: We recognize that every project is unique. Our services are fully customizable, allowing for tailored study designs, including novel dosing regimens and specialized endpoints, to precisely meet your program's needs.
- In-depth Reporting: Our deliverables include comprehensive reports with detailed PK/PD analysis, full histopathology reports, and customized data visualization, providing a complete picture of your drug's in vivo behavior.
How Creative Biolabs' Service Can Assist Your Project?
Our NHP Antibody & Biologic Efficacy services provide a clear, step-by-step path to validate your biologic's efficacy and safety, delivering the data necessary to progress your project with confidence.
01
Required Starting Materials
02
Project Scoping & Protocol Design
03
Animal Husbandry & Dosing
04
Sample Collection & Bioanalysis
05
Data Interpretation & Reporting
Key Deliverables
Our deliverables are designed to be thorough and directly applicable to your drug development program.
- Comprehensive Lab Report
- Raw Data Files (PK, flow cytometry, etc.)
- Histopathology Reports
- Statistical Analysis Report
- Executive Summary and Recommendations
Capabilities & Partnerships
Service-Specific Data
- Annual Sample Size: Over 50,000 samples analyzed per year.
- Turnaround Time (TAT): Typical turnaround of 2 weeks for bioanalytical results.
- Study Pass Rate: 99%+ success rate in meeting study endpoints.
Our Valued Partners
Frequently Asked Questions
Q: How do you choose the right NHP model for my specific bispecific or ADC project?
A: Our team works with you to select the ideal model based on the target biology, mechanism of action, and study goals. Since NHPs have such a high degree of genetic similarity to humans, we can confidently select the most appropriate species and model to ensure the data is highly translational. Let's discuss your project to find the perfect fit.
Q: I am concerned about the potential for immunogenicity in NHPs. How do you manage this?
A: Anti-drug antibody (ADA) formation is a key consideration. We closely monitor for ADA throughout the study, as it can impact PK and efficacy. Our protocols are designed to minimize immunogenicity, and we provide detailed analysis of any ADA response detected to help you understand its potential implications. If you have concerns, we're here to help you navigate this.
Q: How do you handle the complex PK/PD analysis for ADCs and bispecifics?
A: The analysis for these modalities is indeed complex, as you need to track multiple analytes like total antibody, conjugated drug, and free payload. Our state-of-the-art bioanalytical labs are equipped with advanced technologies to accurately quantify these different components. Our team of expert pharmacologists then builds robust PK/PD models to interpret the data, predict human outcomes, and inform your dose selection. Let's talk about how our data can support your clinical trial design.
Q: How do your services compare to using other animal models?
A: While other models like rodents are useful for initial screening, NHPs are the gold standard for late-stage preclinical validation due to their superior biological relevance to humans. This is especially true for bispecifics and ADCs, where target binding and immune responses can be highly species-specific. Our NHP services provide the most predictive data, reducing the risk of clinical failure.
Contact Us
Creative Biolabs is your trusted partner for NHP-based preclinical studies. Our commitment to scientific excellence, combined with our deep expertise in novel biologic modalities, ensures you receive the high-quality data and insights needed to advance your program with confidence. Contact our team for more information and to discuss your project.
Reference
- Becker, Jonas, Julia Fakhiri, and Dirk Grimm. "Fantastic AAV gene therapy vectors and how to find them—random diversification, rational design and machine learning." Pathogens 11.7 (2022). Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.1155/2016/2618575